nach oben

Updates in Surgery

Erschienen in:

09.10.2021 | Review Article

Neoadjuvant therapy for pancreatic cancer

verfasst von: Jean Gugenheim, Anna Crovetto, Niccolo Petrucciani

Erschienen in: Updates in Surgery | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Multimodal treatment including surgery and chemotherapy is considered the gold standard treatment of pancreatic cancer by most guidelines. Neoadjuvant therapy (NAT) has been seen as a possible treatment option for resectable, borderline resectable and locally advanced PaC. The aim of this paper is to offer a state-of-the-art review on neoadjuvant treatments in the setting of pancreatic ductal adenocarcinoma. A systematic literature search was performed using PubMed, Cochrane, Web of Science and Embase databases, in order to identify relevant studies published up to and including July 2021 that reported and analyzed the role of neoadjuvant therapy in the setting of pancreatic carcinoma. Most authors are concordant on the strong role of neoadjuvant therapy in the setting of borderline resectable pancreatic cancers. Recent randomized trials demonstrated improvement of R0 rate and survival after NAT in this setting. Patients with locally advanced cancers may become resectable after NAT, with better results than those obtained with palliative therapies. Even in the setting of resectable cancers, NAT is being evaluated by ongoing randomized trials. Chemotherapy regimens in the setting of NAT and response to NAT are discussed. NAT has an important role in the multimodal treatment of patients with borderline resectable pancreatic cancer. It has a role in patients with locally advanced tumors as it can allow surgical resection in a relevant proportion of patients. For resectable pancreatic cancers, the role of NAT is under evaluation by several randomized trials.

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 1(74):2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155CrossRef

Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K et al (2015) A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer 46:201–211. https://doi.org/10.1007/s12029-015-9724-1CrossRefPubMedPubMedCentral

Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. The Lancet 363:1049–1057. https://doi.org/10.1016/S0140-6736(04)15841-8CrossRef

Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R et al (2018) Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol 3:413–423. https://doi.org/10.1016/S2468-1253(18)30081-5CrossRefPubMed

NCCN guidelines on pancreatic cancer (2020) Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic_blocks.pdf. Accessed October 11, 2020

Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D et al (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 1(26):v56-68. https://doi.org/10.1093/annonc/mdv295CrossRef

Pancreatic cancer in adults: diagnosis and management (2018). National Guideline Alliance (UK) London: National Institute for Health and Care Excellence (UK): Clinical Guidelines. Available from: https://www.ncbi.nlm.nih.gov/books/NBK487233. Accessed October 11, 2020

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 18(350):1200–1210. https://doi.org/10.1056/NEJMoa032295CrossRef

10.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081. https://doi.org/10.1001/jama.2010.1275CrossRefPubMed

11.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 20(379):2395–2406. https://doi.org/10.1056/NEJMoa1809775CrossRef

12.

Tzeng C-WD, Tran Cao HS, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA et al (2014) Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg Off J Soc Surg Aliment Tract 18:16–24. https://doi.org/10.1007/s11605-013-2412-1 (discussion 24-25)CrossRef

13.

Jones CM, Radhakrishna G, Aitken K, Bridgewater J, Corrie P, Eatock M et al (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Br J Cancer 8:1–5. https://doi.org/10.1038/s41416-020-0980-xCrossRef

14.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100CrossRefPubMedPubMedCentral

15.

Heinrich S, Besselink M, Moehler M, van Laethem J-L, Ducreux M, Grimminger P et al (2019) Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer 19:675. https://doi.org/10.1186/s12885-019-5889-5CrossRefPubMedPubMedCentral

16.

Heinemann V, Haas M, Boeck S (2013) Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 24:2484–2492. https://doi.org/10.1093/annonc/mdt239CrossRefPubMed

17.

Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A et al (2016) Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol 42:1533–1539. https://doi.org/10.1016/j.ejso.2016.06.398CrossRefPubMed

18.

Russo S, Ammori J, Eads J, Dorth J (2016) The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol 12:669–685. https://doi.org/10.2217/fon.15.335CrossRefPubMedPubMedCentral

19.

Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS (2014) Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB 16:34–39. https://doi.org/10.1111/hpb.12058CrossRefPubMed

20.

Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM et al (2019) Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: a propensity matching and intention-to-treat analysis. J Surg Oncol 120:976–984. https://doi.org/10.1002/jso.25681CrossRefPubMed

21.

Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F et al (2016) Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery 159:893–900. https://doi.org/10.1016/j.surg.2015.09.018CrossRefPubMed

22.

Zhou W, Wang D, Lou W (2020) Current role of surgery in pancreatic cancer with synchronous liver metastasis. Cancer Control 27(1):1073274820976593. https://doi.org/10.1177/1073274820976593 (PMID: 33238715; PMCID: PMC7791445)CrossRefPubMedPubMedCentral

23.

Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY et al (2017) Predictors of early mortality after surgical resection of pancreatic adenocarcinoma in the era of neoadjuvant treatment. Pancreas 46:183–189. https://doi.org/10.1097/MPA.0000000000000731CrossRefPubMed

24.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17. https://doi.org/10.1097/SLA.0000000000000867CrossRefPubMed

25.

Marchegiani G, Andrianello S, Nessi C, Sandini M, Maggino L, Malleo G et al (2018) Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications. Ann Surg Oncol 25:626–637. https://doi.org/10.1245/s10434-017-6281-9CrossRefPubMed

26.

Yokose T, Kitago M, Matsusaka Y, Masugi Y, Shinoda M, Yagi H et al (2020) Usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Cancer Med 9:4059–4068. https://doi.org/10.1002/cam4.3044CrossRefPubMedPubMedCentral

27.

Zimmermann C, Distler M, Jentsch C, Blum S, Folprecht G, Zöphel K et al (2020) Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). Strahlenther Onkol. https://doi.org/10.1007/s00066-020-01654-4CrossRefPubMedPubMedCentral

28.

Laura A, Anna C, Cinquepalmi M, Giovanni M, Sole MM, Nava AK et al (2020) Is complete pathologic response in pancreatic cancer overestimated? A systematic review of prospective studies. J Gastrointest Surg 24:2336–2348. https://doi.org/10.1007/s11605-020-04697-1CrossRefPubMed

29.

Sell NM, Lee GC, Fernández-Del Castillo C, Ferrone CR, Warshaw AL, Hong TS et al (2020) Evaluation of pathologic response on overall survival after neoadjuvant therapy in pancreatic ductal adenocarcinoma. Pancreas 49:897–903. https://doi.org/10.1097/MPA.0000000000001590CrossRefPubMedPubMedCentral

30.

He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G et al (2018) Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg 268:1–8. https://doi.org/10.1097/SLA.0000000000002672CrossRefPubMed

31.

Perri G, Prakash LR, Katz MHG (2020) Response to preoperative therapy in localized pancreatic cancer. Front Oncol 10:516. https://doi.org/10.3389/fonc.2020.00516CrossRefPubMedPubMedCentral

32.

Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M et al (2020) Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg 271:740–747. https://doi.org/10.1097/SLA.0000000000003049CrossRefPubMed

33.

Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ et al (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14:2088–2096. https://doi.org/10.1245/s10434-007-9384-xCrossRefPubMed

34.

Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L et al (2014) Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 19:266–274. https://doi.org/10.1634/theoncologist.2013-0273CrossRefPubMedPubMedCentral

35.

Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A et al (2020) Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. https://doi.org/10.1097/SLA.0000000000004155CrossRefPubMed

36.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. https://doi.org/10.1056/NEJMoa1011923CrossRefPubMed

37.

Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J et al (2020) Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients—results of the RESPECT-Study. Surg Oncol 35:285–297. https://doi.org/10.1016/j.suronc.2020.08.031CrossRefPubMed

38.

Stessin AM, Meyer JE (2008) Sherr DL (2008) Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 72:1128–1133. https://doi.org/10.1016/j.ijrobp.2008.02.065CrossRefPubMed

39.

Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the lap07 randomized clinical trial. JAMA 315:1844–1853. https://doi.org/10.1001/jama.2016.4324CrossRefPubMed

40.

Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, Weiss MJ, Laheru DA, Wolfgang CL, Herman JM (2015) The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol 22(7):2352–2358. https://doi.org/10.1245/s10434-014-4274-5 (Epub 2015 Jan 7. PMID: 25564157; PMCID: PMC4459890)CrossRefPubMedPubMedCentral

41.

Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 38:1763–1773. https://doi.org/10.1200/JCO.19.02274CrossRefPubMedPubMedCentral

42.

Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L et al (2015) Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 19:1802–1812. https://doi.org/10.1007/s11605-015-2890-4CrossRefPubMed

43.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein W-O, Bruns C et al (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 191:7–16. https://doi.org/10.1007/s00066-014-0737-7CrossRefPubMed

44.

Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, van Eijck CHJ, de Hingh IHJT, Karsten TM, van der Kolk MB, Patijn GA, Liem MSL, van Santvoort HC, Loosveld OJL, de Vos-Geelen J, Zonderhuis BM, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot KB, Dutch Pancreatic Cancer Group (2021) Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21(1):300. https://doi.org/10.1186/s12885-021-08031-z (PMID: 33757440; PMCID: PMC7989075)CrossRefPubMedPubMedCentral

45.

Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG et al (2018) Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 105:946–958. https://doi.org/10.1002/bjs.10870CrossRefPubMedPubMedCentral

46.

Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132. https://doi.org/10.1007/s10434-001-0123-4CrossRefPubMed

47.

Schwarz L, Vernerey D, Bachet J-B, Tuech J-J, Portales F, Michel P et al (2018) Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy—a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 18:762. https://doi.org/10.1186/s12885-018-4663-4CrossRefPubMedPubMedCentral

48.

Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-del Castillo C, Hackert T et al (2018) International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18:2–11. https://doi.org/10.1016/j.pan.2017.11.011CrossRefPubMed

49.

Esnaola NF, Chaudhary UB, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB et al (2014) Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 88:837–844. https://doi.org/10.1016/j.ijrobp.2013.12.030CrossRefPubMedPubMedCentral

50.

Katz MHG, Shi Q, Ahmad SA, Herman JM, de MarshCollisson RWE et al (2016) Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg 151:e161137. https://doi.org/10.1001/jamasurg.2016.1137CrossRefPubMedPubMedCentral

51.

Peters NA, Javed AA, Cameron JL, Makary MA, Hirose K, Pawlik TM et al (2016) Modified Appleby procedure for pancreatic adenocarcinoma: does improved neoadjuvant therapy warrant such an aggressive approach? Ann Surg Oncol 23:3757–3764. https://doi.org/10.1245/s10434-016-5303-3CrossRefPubMed

52.

Ren W, Xourafas D, Ashley SW, Clancy TE (2020) Temporal assessment of prognostic factors in patients with pancreatic ductal adenocarcinoma undergoing neoadjuvant treatment and resection. J Surg Res 257:605–615. https://doi.org/10.1016/j.jss.2020.07.073CrossRefPubMed

53.

Institut de Cancérologie de Lorraine. Two Arm, Prospective, Multicenter Randomized Phase II Trial of Neoadjuvant Modified Folfirinox Regimen, With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (2020). clinicaltrials.gov. Report No.: NCT02676349. Available from: https://clinicaltrials.gov/ct2/show/NCT02676349. Accessed October 11, 2020

54.

Kluger MD, Rashid MF, Rosario VL, Schrope BA, Steinman JA, Hecht EM et al (2018) Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy. J Gastrointest Surg 22:235–241. https://doi.org/10.1007/s11605-017-3556-1CrossRefPubMed

55.

Gurusamy KS, Kumar S, Davidson BR, Fusai G (2014) Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev 2:CD010244. https://doi.org/10.1002/14651858.CD010244.pub2CrossRef

Titel: Neoadjuvant therapy for pancreatic cancer
verfasst von: Jean Gugenheim
Anna Crovetto
Niccolo Petrucciani
Publikationsdatum: 09.10.2021
Verlag: Springer International Publishing
Erschienen in: Updates in Surgery / Ausgabe 1/2022
Print ISSN: 2038-131X
Elektronische ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-021-01186-1

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Transoral thyroid surgery vestibular approach: is there an increased risk of surgical site infections?

Prognosis prediction of extremity and trunk wall soft-tissue sarcomas treated with surgical resection with radiomic analysis based on random survival forest

Ventral Prosthesis Rectopexy for obstructed defaecation syndrome: a systematic review and meta-analysis

Laparoscopic application of the hooking technique for ultrasound-guided minimally invasive liver surgery

E-consensus on telemedicine in colorectal surgery: a RAND/UCLA-modified study

Usefulness of damage control approach in patients with limited acute mesenteric ischemia: a prospective study of 85 patients

Update Chirurgie